title: Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
abstract: The mass balance and metabolite profiles of 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)[U-(14)C]phenyl]acetamide ([(14)C]mirabegron, YM178), a β(3)-adrenoceptor agonist for the treatment of overactive bladder, were characterized in four young, healthy, fasted male subjects after a single oral dose of [(14)C]mirabegron (160 mg, 1.85 MBq) in a solution. [(14)C]Mirabegron was rapidly absorbed with a plasma t(max) for mirabegron and total radioactivity of 1.0 and 2.3 h postdose, respectively. Unchanged mirabegron was the most abundant component of radioactivity, accounting for approximately 22% of circulating radioactivity in plasma. Mean recovery in urine and feces amounted to 55 and 34%, respectively. No radioactivity was detected in expired air. The main component of radioactivity in urine was unchanged mirabegron, which accounted for 45% of the excreted radioactivity. A total of 10 metabolites were found in urine. On the basis of the metabolites found in urine, major primary metabolic reactions of mirabegron were estimated to be amide hydrolysis (M5, M16, and M17), accounting for 48% of the identified metabolites in urine, followed by glucuronidation (M11, M12, M13, and M14) and N-dealkylation or oxidation of the secondary amine (M8, M9, and M15), accounting for 34 and 18% of the identified metabolites, respectively. In feces, the radioactivity was recovered almost entirely as the unchanged form. Eight of the metabolites characterized in urine were also observed in plasma. These findings indicate that mirabegron, administered as a solution, is rapidly absorbed after oral administration, circulates in plasma as the unchanged form and metabolites, and is recovered in urine and feces mainly as the unchanged form.
authors.affiliation: Drug Metabolism Research Laboratories, Astellas Pharma Inc., 2-1-6, Kashima, Yodogawa-ku, Osaka 532-8514, Japan. shin.takusagawa@astellas.com
authors.forename: Shin
authors.initials: S
authors.lastname: Takusagawa
authors.forename: Jan Jaap
authors.initials: JJ
authors.lastname: van Lier
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Suzuki
authors.forename: Masanori
authors.initials: M
authors.lastname: Nagata
authors.forename: John
authors.initials: J
authors.lastname: Meijer
authors.forename: Walter
authors.initials: W
authors.lastname: Krauwinkel
authors.forename: Marloes
authors.initials: M
authors.lastname: Schaddelee
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Sekiguchi
authors.forename: Aiji
authors.initials: A
authors.lastname: Miyashita
authors.forename: Takafumi
authors.initials: T
authors.lastname: Iwatsubo
authors.forename: Marcel
authors.initials: M
authors.lastname: van Gelderen
authors.forename: Takashi
authors.initials: T
authors.lastname: Usui
mesh_terms: D000042:Absorption; D000083:Acetanilides / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D000284:Administration, Oral; D058667:Adrenergic beta-3 Receptor Agonists / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D000328:Adult; D002250:Carbon Radioisotopes; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000737:chemistry; D006801:Humans; D008297:Male; D013058:Mass Spectrometry; D008657:Metabolic Clearance Rate; D015394:Molecular Structure; D022702:Receptors, Adrenergic, beta-3 / Q000378:metabolism*; D013844:Thiazoles / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000493:pharmacokinetics* / Q000652:urine; D055815:Young Adult
chemical_list: D000083:Acetanilides; D058667:Adrenergic beta-3 Receptor Agonists; D002250:Carbon Radioisotopes; D022702:Receptors, Adrenergic, beta-3; D013844:Thiazoles; C520025:mirabegron